Cephalon in trouble over party spirit
February 11, 2011Medical Communications ABPI, ABPI Code of Practice, Cephalon, PMCPA, industry reputation
Cephalon has been criticised by UK authorities for bankrolling “excessive” hospitality at a conference in Lisbon.The company was cited by …
TBWA Paling Walters adds to management board
February 11, 2011Medical Communications Andy Hayley, Ed Shorthose, Steve Morris, TBWA/Paling Walters, appointment, medical communications
London-based advertising agency TBWA\ Paling Walters has promoted Steve Morris and Ed Shorthose to the roles of managing partners. They …
Lilly chief issues warning on UK reforms
February 11, 2011Research and Development, Sales and Marketing John Lechleiter, US health reforms, healthcare reform, lilly, patent box, value-based pricing
Lilly chief executive John Lechleiter has warned that two key UK initiatives could fall seriously short of encouraging investment in …
Innovation is being stifled – Lilly chief executive
February 10, 2011Research and Development, Sales and Marketing Economist 2011 Pharma Summit, US health reforms, healthcare costs, healthcare reform, lilly
Supporting medical innovation should be a fundamental requirement of healthcare reforms, but current public policies are failing to do this, …
Digital Pharma: This is how pharma is using digital
February 10, 2011Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Android, Digital Pharma blog, Facebook, Twitter, disease awareness campaigns, ipad, iphone, social media
Pharma’s use of digital tools, from mobile apps to online campaigns to social media channels, is increasing all the time …
Amarin expands US operations
February 10, 2011Sales and Marketing AMR101, Amarin, Paul Huff, high cholesterol
Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey. …
WHO wants narcolepsy link with swine flu vaccine investigated
February 10, 2011Research and Development, Sales and Marketing Finland Institute, GSK, GlaxoSmithKline, Pandemrix, narcolepsy, swine flu
The World Health Organisation has called for further investigation into GSK’s swine flu vaccine link to sleeping disorder narcolepsy, following …
Dr Mikael von Euler moves to Oncos Therapeutics
February 10, 2011Research and Development Dr Mikael von Euler, Oncos Therapeutics, appointment, research and development
Finnish biotech company Oncos Therapeutics has appointed Dr Mikael von Euler as chief medical officer. He has more than 20 …
Alliance concerned over NHS competition reforms
February 10, 2011Health and Social Care Bill, NHS, NHS Alliance, NHS reforms
The NHS Alliance has called on the Government to clarify major issues around the Health and Social Care Bill which …
Generics force Sanofi into standstill
February 9, 2011Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics
An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …
Shire bags senior research execs from GSK and Abbott
February 9, 2011Research and Development Dr Lawson Macartney, Dr Mario Saltarelli, Shire, appointment, recruitment, research and development
Shire has strengthened its speciality pharmaceuticals business with the appointment of senior research executives from GlaxoSmithKline and Abbott. Dr Lawson …
Pharma-NHS diabetes project begins
February 9, 2011Sales and Marketing AstraZeneca, Lilly UK, MSD, NHS, Nottingham, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, joint working
A joint venture between the NHS, charities and the pharma sector has begun in Nottingham to help treat the city’s …
Teva surges ahead
February 9, 2011Sales and Marketing 2010 pharma results, Copaxone, Teva, Teva Pharmaceutical
Generics giant Teva enjoyed a strong year of growth in 2010, lifted by the acquisition of Ratiopharm, patent expiries of …
Dr Matthias joins Noxxon Pharma
February 9, 2011Research and Development Dr Matthias Baumann, Noxxon Pharma, appointment, research and development
Berlin-based biotech Noxxon Pharma has appointed Dr Matthias Baumann as chief medical officers. He joins from Focus Clinical Drug Development, …
Melanoma: intense competition to be the next milestone treatment
February 9, 2011Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab
A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …
AZ-Targacept depression candidate moves into phase IIb
February 9, 2011Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder
AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …
Early diagnosis key to UK cancer ambition
February 8, 2011Cancer, NHS, NICE
A series of quality standards on cancer care is to be drawn up by NICE as part of a new …
Genzyme to divest pharma intermediates business
February 8, 2011Manufacturing and Production Cerezyme, Corden Pharma Switzerland, Corden Pharma group, Genzyme, International Chemical Investors Group, Sekisui Chemical Co, imiglucerase
Genzyme has agreed to sell off its pharmaceutical intermediates business to International Chemical Investors Group, a holding company which has …
Pharmaceutical facility news in brief
February 8, 2011Manufacturing and Production Baxter International, Famar, Lannett, Qatar Pharma, Sanofi-Aventis, Takeda Pharmaceutical Co
A round-up of news involving manufacturing facilities includes updates from Takeda, Famar/Sanofi, Qatar Pharma, Lannett and Baxter. Takeda Pharmaceutical Co …
Roche eyes ovarian cancer expansion for Avastin
February 8, 2011Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer
Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
